<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598868</url>
  </required_header>
  <id_info>
    <org_study_id>AYM-ViBiD</org_study_id>
    <nct_id>NCT03598868</nct_id>
  </id_info>
  <brief_title>Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression</brief_title>
  <acronym>ViBiD</acronym>
  <official_title>Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate the efficacy of Vortioxetine augmentation in bipolar
      disorder patients with depressive symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators are going to examine the efficacy of vortioxetine
      augmentation in bipolar disorder patients with depressive symptoms.

      The study design is a double-blinded 6-week prospective study. It would be useful for
      clinicians because it will provide new evidence for the effect of vortioxetine in bipolar
      disorder patients with depressive symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Anticipated">September 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>change of Montgomery-Asberg Depression Rating Scale (MADRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions (CGI) scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>change of Clinical Global Impressions (CGI) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>6 weeks</time_frame>
    <description>change of Digit Symbol Substitution Test (DSST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication diary</measure>
    <time_frame>6 weeks</time_frame>
    <description>compliance assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bipolar Disorder Depression</condition>
  <arm_group>
    <arm_group_label>Vortioxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortioxetine 5-20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo augmentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Augmentation : Vortioxetine 10 mg p.o. for week 1, Vortioxetine 5-20 mg p.o. for week 2,4,6.</description>
    <arm_group_label>Vortioxetine</arm_group_label>
    <other_name>Brintellix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Augmentation : Placebo for week 1,2,4,6</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with Bipolar I Disorder, Bipolar II Disorder, Other Specified
             Bipolar and Related Disorder, Unspecified Bipolar and Related Disorder by Diagnostic
             and Statistical Manual (DSM)-V criteria.

          -  18 to 65 years of age

          -  Patients with Montgomery-Åsberg Depression Rating Scale score ≥ 23 (moderate to severe
             depression), after 4 weeks or more of treatment by main medication of mood stabilizer
             or antipsychotics

          -  Patients with Young Mania Rating Scale score lower than 10, after 4 weeks or more of
             treatment by main medication of mood stabilizer or antipsychotics

        Exclusion Criteria:

          -  Currently experiencing manic, hypomanic, or mixed episode

          -  Comorbid with serious medical illness

          -  Comorbid with substance use disorder, medical illness or other neurologic disorder
             that may have caused depressive symptoms other than by bipolar disorder

          -  Pregnancy or Breastfeeding women

          -  Those who are hypersensitive to the main or other ingredient of the medication

          -  Currently on Monoamine oxidase (MAO) inhibitor or those who have discontinued MAO
             inhibitor in the last 14 days

          -  Severe liver disease, severe renal disease

          -  Bleeding tendency/disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Min Ahn, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Jin Rhee, MD</last_name>
    <phone>82 2 2072 2457</phone>
    <email>hellojr1123@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyeyoung Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Min Ahn, MD. PHD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yong Min Ahn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Depression, Bipolar</keyword>
  <keyword>vortioxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

